Las Vegas Sands (NYSE:LVS): JPMorgan sees a number of near-term catalysts for Las Vegas Sands that should move the stock higher, including possible earnings upside in the third quarter related to Macau and a dividend increase in the fourth quarter of this year. The firm raised its price target for shares to $72 from $66 and keeps an Overweight rating on the name.
Marvell (NASDAQ:MRVL): JPMorgan upgraded Marvell to Overweight from Neutral, citing improved execution and solid growth prospects. The firm raised its price target for the shares to $16 from $14.
Palo Alto Networks (NYSE:PANW): After Palo Alto reported higher-than-expected fourth-quarter revenue and in-line earnings per share, Stifel thinks the results should dampen concerns about the company’s growth. The firm reiterates a Buy rating on the stock.
Neurocrine (NASDAQ:NBIX): Deutsche Bank lowered its price target for Neurocrine to $18 from $25 after the company’s Phase II study in tardive dyskinesia missed the primary endpoint. Deutsche still sees many opportunities for upside in 2014, including phase III Elagolix results in endometriosis, and the firm keeps a Buy rating on the stock.